The success rates of the Visian ICL family of lenses are incredibly high. Dr. Parkhurst has written textbooks and lectured all over the world about our results with the ICL, which in every study he has performed to date have equaled or exceeded those of LASIK. In a clinical trial Dr. Parkhurst performed and presented at the American Academy of Ophthalmology in 2010, 96% of eyes and 100% of patients saw 20/20 or better by 3 months after the procedure. In a clinical trial performed by Dr. Parkhurst and presented at the American Society of Cataract and Refractive Surgery, the ICL was found to result in better night vision and contrast sensitivity (determining different shades of gray) at statistically significant degrees more than LASIK.
Dr. Parkhurst was invited by the manufacturer of the ICL, STAAR Surgical, to present his published results to the US FDA, which helped achieve recommendations for approval of the toric ICL in the United States. Dr. Parkhurst’s results with the ICL are among the most cited and referenced research studies in the peer-reviewed, published medical literature